期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗血小板新药替卡格雷临床应用争议 被引量：5

Some disagreement involved in the clinical application of ticagrelor,a new antiplatelet agent
下载PDF
导出
摘要 阿斯利康制药有限公司正在研发的抗血小板新药替卡格雷(ticagrelor,Brilinta)是首个可逆的结合型口服二磷酸腺苷受体拮抗剂,其临床应用颇具潜力。本文汇总近年有关重要国际会议上的专家意见,以便临床能正确合理应用本品,充分发挥其治疗优势。 Being developed by AstraZeneca, ticagrelor is the first reversible oral adenosine diphosphate receptor antagonist and of significant potential in clinical application. This review describes the update on this new antiplatelet agent and some issues about it in clinic.
作者 余佩毅 郭文
机构地区 上海市卢湾区打浦桥街道社区卫生服务中心 上海医药工业研究院信息中心
出处 《世界临床药物》 CAS 2010年第5期I0003-I0005,共3页 World Clinical Drug
关键词 替卡格雷 抗血小板药 安全性 ticagrelor antiplatelet agent safety
分类号 R973 [医药卫生—药品]
  • 相关文献

参考文献7

  • 1Wallentin L.The PLATO Trial[EB/OL].(2009-08-31)[2010-03-04].http://www.crtonline.org/Topics.aspx?CAT=463.
  • 2Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):A randomised double-blind study[J].Lancet,2010,375(9711):283-293.
  • 3Gurbel PA,Bliden KP,Butler K,et al.Randomized double-blind assessment of the ONSET and OFFSET of the antipla-telet effects of ticagrclor vs clopidogrel in patients with stable coronary artery disease.The ONSET/OFFSET study[J].Circulation,2009,120(25):2577-2585.
  • 4Kleiman NS.Why I am not excited about ticagrelor[EB/OL].(2010-02-21)[2010-03-04].http://www.crtmeeting.org/agen-dalist.aspx?EID=11&SID=301.
  • 5Harrington RA.Panel Discussion:how we use antiplatelet therapy for patients with ACS & AMI in 2010[EB/OL].(2010-02-21)[2010-03-04].http://www.crtmeeting.org/agen-dalist.aspx?EID=11&SID=301.
  • 6Rao SV.Panel Discussion:how we use antiplatelet therapy for patients with ACS & AMI in 2010[EB/OL].(2010-02-21)[2010-03-04].http://www.crtmeeting.org/agendalist.aspx?EID=11&SID=301.
  • 7Berger PB.Lessons Learned from the PLATO Trial[EB/OL].(2010-02-21)[2010-03-04].http://www.crtmeeting.org/agendalist.aspx?EID=11&SID=301.

同被引文献78

  • 1周忠江,侯玉清.急性冠状动脉综合征新型抗血小板药物研究进展[J].中华临床医师杂志（电子版）,2012,6(21):6829-6831. 被引量：3
  • 2周玉杰,闫振娴.冠心病抗血小板治疗进展[J].中国医学前沿杂志（电子版）,2009,1(1):51-55. 被引量：1
  • 3谭丽玲,贾三庆,李虹伟,王雷,王明生,赵敏,沈潞华.冠状动脉支架患者氯吡格雷抵抗现象探讨[J].中国心血管病研究,2006,4(10):740-742. 被引量：1
  • 4Ghatak SB, Panchal SJ. Ticagrelor : a novel player in the field of anti-platelet therapy [J ]. J Pharm Res, 2010, 3(6) : 1271-1273.
  • 5Serebruany VL. Adenosine release : a potential explanation for the benefits of ticagrelor in the PLATelet Inhibition and Clinical Outcomes trial [ J ]. Am Heart J, 2011, 161(1) : 1-4.
  • 6Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD 6140-an oral reversible ADP receptor antagonist [ J ]. Haematologica, 2004, 89(Supp1 7) : 14-15.
  • 7Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD 6140 with aspirin in patients with atherosclerosis : a double-blind comparison to clopidogrel with aspirin [ J ]. Eur Heart J, 2006, 27(9) : 1038-1047.
  • 8Fosburgh D.Aspirin and clopidogrel resistance[J].Mayo Clin Proc,2006,81(7):989-990.
  • 9Wiviott SD,Braunwald E.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015.
  • 10Alexopoulos D,Dimitropoulos G.Prasugrel overcomes high onclopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel:the importance of CYP2C19*2 genotyping[J].JACC Cardiovasc Interv,2011,4(4):403-410.

引证文献5

二级引证文献52

世界临床药物
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部